Welcome to the New Mexico Chapter of the American College of Cardiology
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
Latest in Cardiology from ACC.org
- A-CLOSE: Clopidogrel or Extended DAPT in High Ischemic Risk?The A-CLOSE (A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients) trial compared clopidogrel monotherapy with extended dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin...
- ACCEL Lite: SINGLE-AF: Anticoagulation For AFib With Intermediate Stroke RiskIn this episode, Dhanunjaya Lakkireddy MBBS, FACC and Boyoung Joung, MD discuss SINGLE-AF: Anticoagulation for atrial fibrillation with intermediate stroke risk.
- TomorrowLAND: Does Intracoronary Nicorandil Prevent No-Reflow in STEMI Patients Undergoing PCI?Prolonged perfusion balloon predilation and intracoronary delivery of Nicorandil with the Rx Ryusei perfusion balloon did not significantly reduce slow-flow or no-reflow in patients presenting with STEMI undergoing primary PCI, according to findings from the TomorrowLAND trial presented at TCT 2026.
- LIPSIA-STRATEGY: Angiography-Derived vs. Wire-Based FFR to Guide RevascularizationAngiography-derived vessel fractional flow reserve (vFFR)-guided revascularization met the prespecified absolute criterion for noninferiority to wire-based FFR, according to results from the LIPSIA-STRATEGY trial presented at TCT 2026 and simultaneously published in JACC.
- SIRONA: Sirolimus- vs. Paclitaxel-Coated Balloon Angioplasty at 3 YearsComparing sirolimus-coated balloon (SCB) and paclitaxel-coated balloon (PCB) angioplasty in patients with symptomatic femoropopliteal artery disease, no differences in walking capacity and health-related quality of life were noted; however, freedom from clinically driven target-lesion revascularization (TLR) was higher in the SCB group, according to three-year results from the SIRONA trial, presented at TCT 2026 and […]